Ann: 1H22 Results Webcast details, page-24

Absolutely, which comes down to simple business efficiencies of scale and simple performence efficiencies for staff, at the risk of stating the obvious. Too many businesses generally, and bio-tech specifically, have staff that all too often simply don't add enough value to warrant their additional expense. I don't mind medical sales staff expansion however, one of the few areas of medicine that staff are sharply assessed on value-add.

Lets hope revenue growth is above cost growth at this early mid-stage of the business growth, when natural business scale efficiencies should begin to appear in the business metrics - variable costs growth vs return growth from assets should be less linearly correlated as the business naturally grows, unless they go to heavy on R&D. I am too many bio-techs here and overseas who want to run on R&D before they can walk commercially.